BI-3614
BI-3614 is a selective QPCTL/QPCT inhibitor with an IC50 of 4.0 nM for QPCTL and an IC50 of 2.5 nM for QPCT. BI-3614 can be used for research on Alzheimer's disease.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 分子式: C18H15F3N6OS2
- 分子量:452.48
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
製品説明
IC50 & Target
[1]|
CYP3A4 16 μM (IC50) |
CYP2D6 >50 μM (IC50) |
CYP2C8 16 μM (IC50) |
CYP2C19 >50 μM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Raji | EC50 |
0.074 μM
|
Inhibition of SIRPα binding to CD47 on Raji cells using a Jurkat SIRPα reporter cell line.
Inhibition of SIRPα binding to CD47 on Raji cells using a Jurkat SIRPα reporter cell line.
|
5446662 |
体外実験
BI-3614 has a Caco-2 A-B permeability of 3.3 μcm/s and an efflux ratio of 4.2[1].
BI-3614 shows <12 %QH in mouse hepatocytes[1].
BI-3614 exhibits 98.0% binding in mouse plasma[1].
BI-3614 inhibits CYP3A4 and CYP2C8 with an IC50 of 16 μM for both; the IC50 for CYP2D6 and CYP2C19 is >50 μM[1].
BI-3614 (10 μM) does not report off-target activity at a concentration of 10 μM across 38 kinases and 29 Bowes-44 panel targets[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
分子量 452.48
-
分子式 C18H15F3N6OS2
-
SMILES
CC1=C(C2=C(C(F)(F)F)SC3=C2N=C(CSC4=NN=C(N)N4C)NC3=O)C=CC=C1
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
BI-3614 関連分類
HY-190863 関連分類
Powered by Bioz